摘要
目的观察厄罗替尼治疗非小细胞肺癌的疗效和不良反应。方法 46例非小细胞肺癌,其中位年龄为76.2岁,65岁以上者占31例。其中,男22例,女24例。临床分期:ⅢB期12例,Ⅳ期34例,腺癌28例,非腺癌18例,均未接受过一线治疗。治疗方案为厄罗替尼150mg 1次/d单药口服,每月1次查胸腹部CT评价疗效。结果46例患者中,完全缓解2例,部分缓解12例,疾病稳定16例,全组有效率为30.4%,疾病控制率为65.2%。腺癌组:有效率30.7%,疾病控制率70.6%;非腺癌组:有效率为8.5%,疾病控制率为22.6%,两组比较差异有统计学意义(P<0.05)。常见的不良反应为:皮疹和腹泻,Ⅰ和Ⅱ度不良反应皮疹(43.7%)和腹泻(33.6%)未见间质性肺病和常见的血液学毒性出现。结论厄罗替尼对于老年晚期非小细胞肺癌有较好的有效性和安全性。
Objective To evaluate the efficacy and safety of erlotinib as first - line treated elded - patients with ad- vanceded non - small cell lung cancer. Methods 46 elded - patients with advened non - small cell lung cancer, Mid - aged was 76. 2, 31 were over 65 years, clinic stage were 12 I]IB stage and 34 IV stage. 28 of them were adenocareinoma, other were no - adenocareinma. No - one had first - line therapy. They were treated with erlotinib 150mg per day to evaluate the efficacy with CT of chest - abdom. Results 2 of 46 patients were CR, 12 of them were PR, 16 of them were SD, The oral response rate was 30. 4% , disease control rate was 65. 2%, The oral response rate and disease control rate of group of adenoearcinoma were 30. 7% and 70. 6% ; The oral response rate and disease control rate of group of no - adenoeareinoma were 8. 5% and 22. 6%. There was statistically significant between these two groups （ P 〈 0. 05 ） , The common adverse effects were skin rash and diarrhea. Conclusion First - line treated elded - patient with erlotinib was effieive and safety.
出处
《临床合理用药杂志》
2012年第27期39-40,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
厄罗替尼
老年人
癌
非小细胞肺
治疗结果
Erlotinib
Aged
Carcinoma non -small -cell -lung
Treatment outcome
